Precision Cancer Imaging Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Global Cancer Incidence and Screening Demand

Cancer screening programs are expanding while diagnostic capacity remains uneven across countries. The World Health Assembly recognized medical imaging as essential to diagnosis in May 2025 and called on member states to strengthen imaging capacity and address access gaps. This policy direction supports the precision cancer imaging market because earlier detection creates demand for diagnostic workups, staging, and follow-up imaging. Capacity constraints are likely to favor mobile systems, portable CT, low-field MRI, and cloud-connected workflows in places where fixed installations remain difficult to fund. National health agencies in Southeast and South Asia are gradually widening the setting in which imaging equipment can be procured. Suppliers therefore need different commercial models for mature premium sites and for smaller city hospitals that are newly able to adopt advanced imaging.

Expansion of Precision Oncology and Personalized Treatment

Precision oncology requires imaging at several points in a patient’s care pathway, including staging, treatment selection, response assessment, and surveillance. A 2025 review found that AI-assisted imaging reduced reading time by 21% to 53% and improved lesion characterization by 9% to 20% compared with unassisted interpretation. These gains can make repeated imaging workflows more manageable for radiology teams with limited staff. The precision cancer imaging market benefits when imaging becomes a recurring requirement rather than a one-time diagnostic procedure. In prostate cancer, PSMA-PET can support selection, restaging, and post-treatment evaluation across the patient pathway. Work by the Cardiovascular and Interventional Radiological Society of Europe on imaging biomarkers may also support the use of validated imaging endpoints in clinical studies.

Adoption of Molecular Imaging and Targeted Radiopharmaceuticals

Targeted radiopharmaceuticals are linking PET imaging more closely to treatment decisions. The United States Food and Drug Administration approved Gozellix in March 2025, a gallium-68 gozetotide PSMA-PET imaging agent with a shelf life of up to 6 hours.^[1] The longer shelf life can extend access to PET camera sites that could not be served reliably by earlier supply models. A 2025 scientific review described the expanding clinical role of approved PSMA-PET agents in prostate cancer imaging. The precision cancer imaging market gains when tracer availability, scanner capacity, and therapeutic use are planned together. GE HealthCare’s Care Alliance with the University of Rochester Medical Center includes cyclotron installation for in-house production of short-lived radioisotopes, showing how local production can reduce supply risk for PET programs.

Integration of Artificial Intelligence and Quantitative Image Analytics

AI is being used both to sort routine imaging studies and to assist radiologists during interpretation. A 2025 study found that AI used as a prescreener reduced lung CT recall rates by 13.5% and reduced mean interpretation time to 143 seconds. The same study found that an assistant model increased recall rates when its suggestions influenced readers, which highlights the need for careful workflow design. AI platforms that reduce routine workload may have a clearer clinical role than products that only add another recommendation layer. The FDA cleared InferRead Lung CT.AI in April 2025 for automated detection of pulmonary nodules as small as 4 mm in asymptomatic populations.^[2] The Philips-coordinated PreciseOnco program also combines AI-driven spectral CT, robotic guidance, and real-time imaging feedback in cancer treatment studies.

High Capital and Lifecycle Cost of Advanced Imaging Systems

PET/CT, total-body PET, and high-field MRI installations require substantial equipment, facility, and service investment. Large health systems are responding through multi-year agreements that combine equipment, maintenance, software, and training. GE HealthCare signed a 14-year Care Alliance with UC San Diego Health in October 2025 covering several imaging and nuclear medicine modalities. These agreements can reduce immediate purchasing barriers for integrated health systems. They can also narrow procurement options when hardware, AI software, and service are included under a single supplier relationship. The precision cancer imaging market may therefore see imaging capacity concentrated in larger cancer centers and academic systems that can support high-throughput use.

Shortage of Specialized Imaging and Nuclear Medicine Professionals

The supply of trained radiologists, radiographers, medical physicists, and nuclear medicine specialists limits the pace of service expansion. A 2025 assessment of MRI capacity in Southeast Asia identified insufficient resources, long waiting times, and shortages of trained staff as key barriers. AI can help manage routine reads, but it does not replace specialist oversight for tracer administration, dosimetry, and interpretation in theranostic pathways. This leaves the fastest-growing precision applications dependent on a narrow pool of trained professionals. The World Health Assembly’s 2025 action on imaging capacity offers a policy response, but training pipelines take years to produce qualified staff. European nuclear medicine facilities must also meet applicable radiation safety and credentialing requirements under the EU Basic Safety Standards Directive.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Precision Cancer Imaging Market Segment Analysis

Hardware held 56.37% of the precision cancer imaging market share in 2026, reflecting the large installed base of PET, CT, MRI, and ultrasound systems. Every clinical imaging workflow still depends on physical scanner infrastructure, even where AI is used for interpretation or care coordination. This gives hardware suppliers recurring revenue opportunities from maintenance, upgrades, replacement cycles, and service contracts. Hospitals also need dependable uptime and trained personnel to use these systems safely. Multi-year enterprise arrangements are becoming a practical way to cover equipment, support, and staff training together. GE HealthCare’s 2025 agreement with UC San Diego Health covered X-ray, CT, PET/CT, PET/MR, SPECT/CT, MRI, and nuclear medicine services. Such arrangements support established equipment suppliers, but they can make access more difficult for independent software providers.

Software is forecast to record a 12.81% CAGR through 2032 within the precision cancer imaging market. Growth is supported by AI tools that assist image review and enterprise platforms that connect images, reports, and clinical decisions. The FDA clearance of InferRead Lung CT.AI shows that specific software functions with defined performance claims can move through established regulatory routes. Software can be purchased with a new scanner or deployed across a mixed fleet of equipment. That flexibility broadens its use in hospital networks seeking common analytics and workflow tools. Its value still depends on validation, interoperability, and clinician acceptance. The precision cancer imaging market is therefore likely to retain hardware as its base while software becomes more closely embedded in care delivery.

PET held 33.47% of the precision cancer imaging market share in 2026. Its leading position reflects the use of molecular imaging in prostate cancer staging, biochemical recurrence detection, and theranostic selection. PSMA-PET agents are increasingly tied to radioligand therapy decisions, which can create repeat imaging needs during a patient’s care. Gozellix received FDA approval in March 2025 as a PSMA-PET agent with an extended 6-hour shelf life. This formulation can support delivery to more PET sites. PET also has a central role where imaging is used to determine whether a patient is suitable for targeted treatment. The modality’s role is consequently moving beyond a staging support function.

MRI is forecast to expand at a 13.42% CAGR through 2032, the fastest rate among the listed modalities. It benefits from wider use in dense-breast imaging and from prostate imaging before biopsy. A 2025 review reported evidence that AI-supported imaging can reduce reading time while improving lesion characterization. MRI offers detailed soft-tissue visualization without ionizing radiation, which supports its use in repeat assessment pathways. CT continues to serve high-volume staging, lung screening, and treatment planning needs. Ultrasound and contrast-enhanced ultrasound remain accessible options in breast and liver cancer evaluation. Together, these modalities show how the precision cancer imaging market can meet different clinical and cost needs.

Lung cancer held 26.51% of the precision cancer imaging market revenue share in 2026. CT screening and PET/CT staging support its large imaging volume across diagnosis and treatment planning. Low-dose CT remains a key tool for screening eligible adults, while PET helps evaluate the extent of disease and treatment response. AI is also being developed to support lung CT workflow management. InferRead Lung CT.AI received FDA clearance for automated pulmonary nodule detection in April 2025. Breast and colorectal cancer also create substantial imaging needs through mammography, MRI, CT, and PET pathways. The broader cancer mix keeps demand distributed across several imaging technologies.

Prostate cancer is forecast to expand at a 13.69% CAGR through 2032, the fastest rate among cancer types. Its growth is linked to the pairing of PSMA-PET imaging with radioligand therapy. FDA approval of Pluvicto for earlier use before chemotherapy in March 2025 expanded the clinical setting in which PSMA-positive metastatic castration-resistant prostate cancer can be treated.^[3] FDA approval of the Illuccix label expansion in June 2025 supported use of the imaging agent for patient selection in the pre-taxane setting. These changes make imaging part of therapeutic decision-making. The imaging pathway may include selection, interim evaluation, and end-of-treatment assessment. This makes prostate cancer an important test case for care models where diagnostic imaging and therapy are commercially connected.

Diagnosis and staging accounted for 37.91% of the precision cancer imaging market in 2026. Biomarker-guided staging helps clinicians determine treatment approaches across solid tumors. The quality of this assessment can influence the next clinical decision, including surgery, radiation, systemic therapy, or further molecular imaging. A 2025 review described improved lesion characterization with AI-assisted imaging in relevant clinical studies. Screening and early detection are also growing as lung and breast programs widen access in major markets. Treatment planning uses imaging data for radiotherapy, dosimetry, and procedure guidance. These uses make accurate image acquisition and reporting central to oncology operations.

Treatment monitoring and response assessment is forecast to grow at a 14.43% CAGR through 2032. Theranostic protocols can require scans during treatment and at completion, raising the number of imaging interactions per patient. Immunotherapy also creates situations where imaging helps distinguish true progression from treatment-related changes. Quantitative PET and MRI-based radiomics are being explored for these difficult response assessments. The application depends on clinical validation because a mistaken conclusion can lead to an unnecessary change in care. Repeat imaging creates opportunities for providers to maintain consistent protocols over time. It also raises the importance of specialist interpretation and data continuity across the precision cancer imaging market.

On-premises systems held 76.22% of the precision cancer imaging market revenue share in 2026. Large hospitals often keep imaging data and core systems within their own environments to maintain direct operational control. This approach can help organizations manage sensitive oncology archives and customize local AI workflows. It can also support fast response requirements in procedural or high-throughput settings. Compliance factors include HIPAA requirements in the United States and the General Data Protection Regulation in the European Union. These rules influence how patient images are stored, accessed, and transferred. On-premises deployment will therefore remain relevant where clinical risk, privacy, and workflow speed are central concerns.

Cloud-based deployment is forecast to expand at a 14.82% CAGR through 2032. Multi-site networks can use cloud services to centralize governance, standardize software versions, and add capacity without purchasing local server infrastructure. Sectra signed a 7-year contract with a U.S. cancer center in April 2025 for its Sectra One Cloud enterprise imaging platform.^[4] The contract covered several diagnostic disciplines under a managed service arrangement. This model changes spending from an upfront capital purchase toward a continuing service agreement. Cloud deployment can also help teleradiology and distributed cancer networks share standardized tools. Data protection, governance, and third-party processing controls remain important conditions for adoption.

Hospitals and clinics held 52.36% of the precision cancer imaging market revenue share in 2026. They remain the principal settings for diagnosis, treatment, inpatient monitoring, and complex imaging procedures. Their scale can support expensive PET/CT, MRI, and nuclear medicine equipment. Academic medical centers also combine clinical care with research, which supports early use of advanced protocols and imaging analytics. The University of Rochester Medical Center agreement with GE HealthCare includes cyclotron infrastructure to support short-lived isotope production. Diagnostic imaging centers add capacity by offering outpatient PET and MRI services. The provider landscape consequently includes both large hospital networks and specialized outpatient sites.

Cancer care centers are forecast to expand at a 15.67% CAGR through 2032. These facilities are designed to bring imaging, treatment planning, and therapy delivery into one oncology pathway. Willis Knighton Health completed a nuclear oncology expansion in March 2025, adding a GE HealthCare StarGuide SPECT/CT system and a second PET/CT scanner. The expansion shows how dedicated cancer providers are building theranostic capability into their service mix. Integrated centers may be able to coordinate scan scheduling, therapy selection, and response review more closely than referral-based models. Their growth also increases demand for specialist staff, radiopharmaceutical supply, and interoperable clinical systems. This creates a clear opportunity for suppliers that can support the entire oncology imaging workflow.

Geography Analysis

North America: Reimbursement Reform Amplifies Installed-Base Advantage

North America held 39.48% of the precision cancer imaging market revenue share in 2026. The region has a dense base of academic cancer centers, community hospitals, and freestanding imaging facilities. It also has a strong foundation for PET, CT, MRI, and nuclear medicine services. Regulatory and payment decisions influence which imaging agents and technologies reach patients. FDA approvals in 2025 for Gozellix and the earlier use of Pluvicto supported the use of PSMA-directed imaging and therapy in prostate cancer pathways. Telix also reported FDA approval of an Illuccix label expansion for pre-taxane patient selection in June 2025. Long-term equipment alliances are reinforcing the role of large health systems in advanced imaging adoption. GE HealthCare’s 14-year UC San Diego Health agreement is one example of this model. The region’s structural advantage comes from its installed base, specialist workforce, and ability to translate regulatory approvals into clinical use.

Asia-Pacific: Infrastructure Deficit Becomes the Market Opportunity

Asia-Pacific is forecast to expand at a 15.88% CAGR through 2032. Cancer burden, hospital modernization, and the need for more imaging access are supporting growth across the region. The available MRI capacity remains limited in many Southeast Asian health systems. A 2025 assessment identified shortages of MRI equipment and trained professionals, along with long waiting times, as major barriers to access. This capacity gap supports demand for practical equipment choices and for tools that improve workflow efficiency. The World Health Assembly’s 2025 resolution on medical imaging offers policy support for national capacity-building efforts. Japan and South Korea are earlier adopters of advanced imaging and AI-enabled workflows, while other parts of the region require broader infrastructure development. Suppliers that can pair equipment with local support, training, and scalable service models are better positioned to address this varied demand.

Global Demand Patterns Beyond Core Regions

Europe has established nuclear medicine services and remains important for molecular imaging, theranostics, and quantitative imaging work. European facilities operate within radiation safety and clinical quality frameworks that influence facility design, staff qualifications, and tracer use. The EU Basic Safety Standards Directive is a relevant compliance factor for nuclear medicine services. The United Kingdom and Italy are advancing lung cancer CT screening approaches, while AI assessment tools are being considered as a way to manage reading workloads. The EU AI Act also affects medical AI tools classified as high-risk systems, encouraging suppliers to build stronger documentation, monitoring, and explainability practices. In the Middle East and Africa, imaging adoption is at an earlier stage outside larger health systems, while access is constrained by financing and workforce limits. South American use is concentrated in major urban cancer centers, with nuclear medicine capability influencing where advanced PET services can operate. Across these mixed regions, the International Atomic Energy Agency’s radiation protection frameworks shape planning for new nuclear medicine facilities. These requirements make service capability, training, and regulatory readiness as important as equipment delivery for the precision cancer imaging market.